Skip to main content Skip to main navigation menu Skip to site footer

Kadar luteinizing hormone yang tinggi menjadi faktor risiko melasma pada pria

  • Henny Wijaya ,
  • Ketut Kwartantaya Winaya ,
  • Ni Made Dwi Puspawati ,
  • IGAA Praharsini ,
  • IGN Darmaputra ,
  • Ratih Vibriyanti Karna ,


Abstract

Introduction: Melasma is a hyperpigmented disorder that generally occurs on the face, mostly in women. Meanwhile, the incidence of melasma in men is still little documented, especially in studies that specifically discuss hormonal risk factors for the occurrence of melasma in men. Therefore, this study aimed to evaluate the relationship between high levels of the luteinizing hormone as a risk factor for melasma in men.

Methods: The design used is an analytic retrospective and case-control method. The research location is the Dermatology and Venereology Polyclinic, the cosmetic-medical subdivision of the Central General Hospital Prof. Dr. IGNG Ngoerah, Denpasar, Bali, from June 2022 to August 2022. The melasma samples were paired with non-melasma samples based on age, Fitzpatrick type, and duration of sun exposure. Data were obtained using medical records and analyzed univariate to multivariate through SPSS application with a p-value of 0.05.

Results: A total of 60 respondents were included in this study, 30 people with melasma cases and 30 as controls. Based on the characteristics of the respondents, the mean age was 48.83±6.30 years. Based on the analysis, several factors significantly affect the occurrence of melasma in men: family history, duration of sun exposure > 6 hours, and high serum LH. levels (p<0.05). The results of logistic regression analysis showed serum LH levels > 15.09 mIU/ml (OR: 6.986; 95%CI: 1.905-25,622; p=0.003). This result shows that the risk factor for LH serum levels of 15.09 IU/ml has a 6.9 times risk of melasma in male patients compared to those with LH levels < 15.09. The results of the Pearson correlation test showed a strong relationship between high serum LH Levels and an increase in the patient's MASI score (r=0.982; p<0.001).

Conclusion: It can be concluded that high serum LH levels are the main risk factor for melasma in men.

 

Latar Belakang: Melasma merupakan kelainan hiperpigmentasi yang umumnya terjadi pada daerah wajah dan mayoritas terjadi wanita. Sedangkan, kejadian melasma pada pria masih sedikit didokumentasikan, khususnya studi yang membahas secara spesifik faktor risiko hormonal terhadap terjadinya melasma pada pria. Oleh karenanya, penelitian ini bertujuan mengevaluasi hubungan antara kadar luteinizing hormone yang tinggi sebagai faktor risiko melasma pada pria.

Metode: Desain yang digunakan yakni retrospektif analitik dan metode case control. Lokasi penenlitian yakni Poliklinik Kulit dan Kelamin subdivisi kosmedik Rumah Sakit Umum Pusat Prof. Dr. I.G.N.G. Ngoerah, Denpasar, Bali, mulai bulan Juni 2022 hingga Agustus 2022. Sampel melasma dipasangkan dengan sampel non melasma berdasarkan usia, tipe kulit Fitzpatrick, dan lama paparan matahari. Data diperoleh dengan menggunakan rekam medis dan dianalisis secara univariat sampai multivariat melalui aplikasi SPSS dengan nilai p ≤ 0,05.

Hasil: Total terdapat 60 responden yang masuk dalam studi ini, 30 orang dengan kasus melasma dan 30 orang sebagai kontrol. Berdasarkan karakteristik responden diperoleh memiliki rerata usia 48,83±6,30 tahun. Berdasarkan analisis diperoleh beberapa faktor yang berpengaruh signifikan terhadap terjadinya melasma pada pria adalah, riwayat keluarga, lama paparan sinar matahari > 6 jam, dan tingginya kadar serum LH (p<0,05). Hasil analisis regresi logistik menunjukan kadar serum LH > 15,09 mIU/ml (AOR: 6,986; 95%CI:1,905-25,622; p=0,003). Pada hasil ini menunjukan nilai faktor risiko kadar serum LH ≥ 15,09 IU/ml memiliki risiko sebesar 6,9 kali terjadi melasma pada pasien laki-laki dibandingkan yang memiliki kadar LH < 15,09. Hasil uji korelasi Pearson menunjukan adanya hubungan kuat antara kadar serum LH tinggi dengan peningkatan skor MASI pasien (r=0,982; p<0,001)

Simpulan: Dapat disimpulkan bahwa kadar serum LH yang tinggi menjadi faktor risiko utama kejadian melasma pada pria

Keywords: Faktor risiko luteinizing hormone melasma pria

References

  1. Sarkar R, Ailawadi P, Garg S. Melasma in men: A review of clinical, etiological, and management issues. The Journal of clinical and aesthetic dermatology. 2018;11(2):53.
  2. Sarkar R, Puri P, Jain RK, Singh A, Desai A. Melasma in men: a clinical, aetiological and histological study. Journal of the European Academy of Dermatology and Venereology. 2010;24(7):768-72. https://doi.org/10.1111/j.1468-3083.2009.03524.
  3. Vachiramon V, Suchonwanit P, Thadanipon K. Melasma in men. Journal of Cosmetic Dermatology. 2012;11(2):151-7. https://doi.org/10.1001/archderm.143.3.424.
  4. Pandya AG, Hynan LS, Bhore R, Riley FC, Guevara IL, Grimes P, Nordlund JJ, Rendon M, Taylor S, Gottschalk RW, Agim NG. Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method. Journal of the American Academy of Dermatology. 2011;64(1):78-83. https://doi.org/10.1016/j.jaad.2009.10.051.
  5. Melyawati LS, Bernadette I, Legiawati L, Surachmiati L. Perkembangan terbaru etiopatogenesis melasma. Media Derm. Venereol. Indones. 2014;41(3):133-8.
  6. Muthusami KR, Chinnaswamy P. Effect of chronic alcoholism on male fertility hormones and semen quality. Fertility and sterility. 2005 Oct 1;84(4):919-24. https://doi.org/10.1016/j.fertnstert.2005.04.025
  7. Ilahi S, Ilahi TB. Anatomy, Adenohypophysis (Pars Anterior, Anterior Pituitary). InStatPearls [Internet] 2020. StatPearls Publishing.
  8. Purwaningrum NM, Suryantari SA, Karna NL. Efektivitas terapi sistemik dan topikal dalam pengobatan melasma. Gema kesehatan. 2020;12(2):88-98.
  9. Suryantari SA, Sweta NP, Veronica E, Mulya IG, Karna NL. Systematic review of melasma treatments: advantages and disadvantages. Bali Dermatology and Venereology Journal. 2020;3(2).
  10. Maeda K, Naganuma M, Fukuda M, Matsunaga J, Tomita Y. Effect of pituitary and ovarian hormones on human melanocytes in vitro. Pigment cell research. 1996;9(4):204-12. https://doi.org/10.1111/j.1600-0749.1996.tb00110.
  11. Handel AC, Miot LD, Miot HA. Melasma: a clinical and epidemiological review. Anais brasileiros de dermatologia. 2014 Sep;89:771-82. https://doi.org/10.1590/abd1806-4841.20143063.
  12. Majid I, Aleem S. Melasma: Update on Epidemiology, Clinical Presentation, Assessment, and Scoring. J Ski Stem Cell [Internet]. 2022;8(4):e120283. Tersedia di: https://brieflands.com/articles/jssc-120283.html [Diakses pada tanggal 21 Agustus 2022].
  13. Majid I, Haq I, Imran S, Keen A, Aziz K, Arif T. Proposing melasma severity index: A new, more practical, office-based scoring system for assessing the severity of melasma. Indian journal of dermatology. 2016;61(1):39. https://doi.org/10.4103/0019-5154.174024.
  14. Achar A, Rathi SK. Melasma: a clinico-epidemiological study of 312 cases. Indian journal of dermatology. 2011;56(4):380. https://doi.org/10.4103/0019-5154.84722.
  15. Tamega AD, Miot LD, Bonfietti C, Gige TC, Marques ME, Miot HA. Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women. Journal of the European Academy of Dermatology and Venereology. 2013;27(2):151-6. https://doi.org/10.1111/j.1468-3083.2011.04430.
  16. Setyawati NK. Insiden dan Profil Melasma di Rumah Sakit Umum Pusat Sanglah Denpasar Periode Januari 2014 Sampai Desember 2014. E-Jurnal Medika Udayana. 2019;8(2).
  17. Asditya A, Sukanto H. Profile of melasma patients: a retrospective study. Berkala Ilmu Kesehatan Kulit dan Kelamin. 2017;29(3):220-8..
  18. Espósito, A. C. C., Cassiano, D. P., Silva, C. N. da, Lima, P. B., Dias, J. A. F., Hassun, K., Bagatin, E., Miot, L. D. B., & Miot, H. A. Update on Melasma—Part I: Pathogenesis. Dermatology and Therapy. 2022: 1–22. https://doi.org/10.1007/S13555-022-00779-X
  19. Aishwarya K, Bhagwat PV, John N. Current concepts in melasma-A review article. Journal of Skin and Sexually Transmitted Diseases. 2020;2(1):13-7. https://doi.org/10.25259/JSSTD_34_2019
  20. Lee HC, Thng TG, Goh CL. Oral tranexamic acid (TA) in the treatment of melasma: a retrospective analysis. Journal of the American Academy of Dermatology. 2016;75(2):385-92. https://doi.org/10.1016/j.jaad.2016.03.001.
  21. Pratama GM, Hartawan IG, Indriani IG, Yusrika MU, Suryantari SA, Satyarsa AB, Sudarsa PS. Potensi Ekstrak Spirulina platensis sebagai Tabir Surya terhadap Paparan Ultraviolet B. J Med. 2020;2(6):205-17.
  22. Abdalla MA. Melasma Clinical Features, Diagnosis, Epidemiology and Etiology: An Update Review. Siriraj Medical Journal. 2021;73(12):841-50. https://doi.org/10.33192/SMJ.2021.109.

How to Cite

Wijaya, H., Winaya, K. K. ., Puspawati, N. M. D. ., Praharsini, I. ., Darmaputra, I. ., & Karna, R. V. . (2023). Kadar luteinizing hormone yang tinggi menjadi faktor risiko melasma pada pria. Intisari Sains Medis, 14(1), 168–175. https://doi.org/10.15562/ism.v14i1.1486
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
0

Total
0

Share

Search Panel

Henny Wijaya
Google Scholar
Pubmed
ISM Journal

Ketut Kwartantaya Winaya
Google Scholar
Pubmed
ISM Journal

Ni Made Dwi Puspawati
Google Scholar
Pubmed
ISM Journal

IGAA Praharsini
Google Scholar
Pubmed
ISM Journal

IGN Darmaputra
Google Scholar
Pubmed
ISM Journal

Ratih Vibriyanti Karna
Google Scholar
Pubmed
ISM Journal